-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the accelerating development of the pharmaceutical industry, the scale of China's API market has been growing
.
It has risen from US$130.
8 billion in 2015 to US$175 billion in 2019, with a compound annual growth rate of 7.
5%
.
According to this development trend, the scale of China's API industry is expected to exceed 250 billion yuan in 2022
.
It is understood that due to the optimistic prospects for the development of APIs, many domestic API companies have begun to accelerate industrial upgrading, and are trying to seize the market high ground in this field through various layouts
.
For example, in November last year, the construction of peptide APIs of Xingputai Biopharmaceutical Co.
, Ltd.
with a total investment of 1.
03 billion yuan kicked off in Taixing Economic Development Zone
.
The project is invested and constructed by Shanghai Shengpu Zetai Pharmaceutical Technology Co.
, Ltd.
with a total investment of 1.
03 billion yuan.
It is expected to build an annual output of 1,100 kilograms of high value-added polypeptide APIs, covering diabetes treatment, anticoagulation, varicose vein treatment and other polypeptide treatments field
.
In addition, in recent years, including Hendi Pharmaceutical, Aoxiang Pharmaceutical, Fuxiang Co.
, Ltd.
, Tianyu Co.
, Ltd.
, Anglikang, Xianju Pharmaceutical, etc.
, have also announced fixed increase plans one after another, and the funds raised are all used to expand production.
In addition, most of the fundraising products are in the introduction period or the rapid volume period
.
The industry believes that from the above point of view, it has fully reflected the high prosperity of China's API industry and the attention of capital to it
.
However, although the API market is developing continuously, it is currently facing many challenges; for example, under the high pressure of a series of energy-saving and emission reduction policies, API companies are facing strict environmental supervision; boost
etc.
It is worth mentioning that industry analysts believe that these factors will also force raw material companies to upgrade related pharmaceutical equipment and generate more demand
.
In fact, it is understood that in the "Major Project for High-Quality Development of APIs" released last year, it was proposed to support the development of internationally advanced microchannel reactors, peptide synthesizers, nucleic acid synthesizers, new crystallizers, and highly airtight isolation.
high-end equipment such as air dryer, fluidized bed dryer, ultrafine powder jet mill, fully automatic synthesis reactor, etc.
.
In addition, it will develop and apply high-efficiency energy-saving equipment for high-energy-consuming links such as air compression, refrigeration, water production, distillation, fermentation, and three-waste treatment, improve the level of thermal recycling, and reduce energy consumption
.
Therefore, under the background that the accelerated transformation and upgrading of the API industry has become the general trend, industry insiders believe that in order to meet the needs of upgrading, the demand for green, environmentally friendly, high-efficiency and energy-saving API equipment will continue to grow
.
Affected by this, related API equipment companies are expected to benefit, and the future growth space will become more and more broad
.
It is worth mentioning that some equipment companies have seen the opportunity and are constantly developing safe, environmentally friendly and cost-effective environmentally friendly products to meet market requirements
.
For example, some pharmaceutical equipment companies have developed a new combined multi-effect distilled water machine that can provide sterile pharmaceuticals, injections, large infusions, and biopharmaceuticals for the pharmaceutical industry
.
According to the staff, this equipment can run continuously for 240 days, saving 65% of the energy in terms of saving water, saving industrial steam, and reducing the pressure of enterprise sewage
.
In addition, the technology adopted by the machine can save 21 million tons of standard coal and 340 million tons of drinking water every year
.
In general, while the API industry and enterprises continue to develop, they will continue to force domestic API production equipment manufacturers to increase investment in research and development, continue to make new breakthroughs in high-end fields, and promote the better development of the API industry
.
.
It has risen from US$130.
8 billion in 2015 to US$175 billion in 2019, with a compound annual growth rate of 7.
5%
.
According to this development trend, the scale of China's API industry is expected to exceed 250 billion yuan in 2022
.
It is understood that due to the optimistic prospects for the development of APIs, many domestic API companies have begun to accelerate industrial upgrading, and are trying to seize the market high ground in this field through various layouts
.
For example, in November last year, the construction of peptide APIs of Xingputai Biopharmaceutical Co.
, Ltd.
with a total investment of 1.
03 billion yuan kicked off in Taixing Economic Development Zone
.
The project is invested and constructed by Shanghai Shengpu Zetai Pharmaceutical Technology Co.
, Ltd.
with a total investment of 1.
03 billion yuan.
It is expected to build an annual output of 1,100 kilograms of high value-added polypeptide APIs, covering diabetes treatment, anticoagulation, varicose vein treatment and other polypeptide treatments field
.
In addition, in recent years, including Hendi Pharmaceutical, Aoxiang Pharmaceutical, Fuxiang Co.
, Ltd.
, Tianyu Co.
, Ltd.
, Anglikang, Xianju Pharmaceutical, etc.
, have also announced fixed increase plans one after another, and the funds raised are all used to expand production.
In addition, most of the fundraising products are in the introduction period or the rapid volume period
.
The industry believes that from the above point of view, it has fully reflected the high prosperity of China's API industry and the attention of capital to it
.
However, although the API market is developing continuously, it is currently facing many challenges; for example, under the high pressure of a series of energy-saving and emission reduction policies, API companies are facing strict environmental supervision; boost
etc.
It is worth mentioning that industry analysts believe that these factors will also force raw material companies to upgrade related pharmaceutical equipment and generate more demand
.
In fact, it is understood that in the "Major Project for High-Quality Development of APIs" released last year, it was proposed to support the development of internationally advanced microchannel reactors, peptide synthesizers, nucleic acid synthesizers, new crystallizers, and highly airtight isolation.
high-end equipment such as air dryer, fluidized bed dryer, ultrafine powder jet mill, fully automatic synthesis reactor, etc.
.
In addition, it will develop and apply high-efficiency energy-saving equipment for high-energy-consuming links such as air compression, refrigeration, water production, distillation, fermentation, and three-waste treatment, improve the level of thermal recycling, and reduce energy consumption
.
Therefore, under the background that the accelerated transformation and upgrading of the API industry has become the general trend, industry insiders believe that in order to meet the needs of upgrading, the demand for green, environmentally friendly, high-efficiency and energy-saving API equipment will continue to grow
.
Affected by this, related API equipment companies are expected to benefit, and the future growth space will become more and more broad
.
It is worth mentioning that some equipment companies have seen the opportunity and are constantly developing safe, environmentally friendly and cost-effective environmentally friendly products to meet market requirements
.
For example, some pharmaceutical equipment companies have developed a new combined multi-effect distilled water machine that can provide sterile pharmaceuticals, injections, large infusions, and biopharmaceuticals for the pharmaceutical industry
.
According to the staff, this equipment can run continuously for 240 days, saving 65% of the energy in terms of saving water, saving industrial steam, and reducing the pressure of enterprise sewage
.
In addition, the technology adopted by the machine can save 21 million tons of standard coal and 340 million tons of drinking water every year
.
In general, while the API industry and enterprises continue to develop, they will continue to force domestic API production equipment manufacturers to increase investment in research and development, continue to make new breakthroughs in high-end fields, and promote the better development of the API industry
.
